French digital health startup Ludocare has received a pivotal initial recommendation for its digital therapy, "Joe," to be reimbursed by France's national health system. The Haute Autorité de Santé (HAS), the country's health technology assessment body, has issued a favorable opinion for its inclusion in the "List of Reimbursable Products and Services" (LPPR).

Joe is a prescription-only digital therapeutic device designed to treat amblyopia, or "lazy eye," in children aged 4 to 10. It uses a gamified approach with 3D glasses and a tablet to deliver personalized visual exercises, aiming to improve visual acuity. The HAS assessment concluded that Joe provides a "minor improvement in medical benefit" compared to standard care (patching), while acknowledging its service benefit for treatment adherence and monitoring.

This positive opinion is a critical first step. The final decision on pricing and reimbursement rate now rests with the Economic Committee for Health Products (CEPS). If approved, Joe would become one of the first digital therapies for amblyopathy to be covered by French national insurance, potentially making the treatment more accessible.

Founded in 2019, Ludocare has raised €2.5 million to date. The company highlights that its solution can reduce treatment time from an average of 12-18 months with patching to approximately 3 months. A broader European market access strategy is planned following potential success in France.

L’article Premier avis favorable pour le remboursement de la thérapie numérique Joe de la startup Ludocare est apparu en premier sur Maddyness - Le média pour comprendre l'économie de demain.